Ocular Therapeutix (OCUL) Initiated At Oppenheimer And RBC Capital Markets

Analysts at Oppenheimer initiated coverage on Ocular Therapeutix (OCUL) with a ‘Outperform’ rating and a $25 price target in a research report issued to clients on Tuesday. The firm sees the company as an appealing platform play in the ophthalmology space, and believes that at current levels even a conservative view of peak share suggests […] View the full post at: Ocular Therapeutix (OCUL) Initiated At Oppenheimer And RBC Capital Markets Related posts: Citigroup May Need $10 bln More in New Capital I’m Still Going Long and Hoping the Markets Go Down Prudential Seeks Hong Kong Listing Before Capital Increase